Login to Your Account



The power of GOULD: Amgen's LDL-C registry designed to mine PCSK9, trends in treatment

By Randy Osborne
Staff Writer

Wednesday, January 4, 2017

Scott Wasserman, Amgen Inc.'s vice president of global development, told BioWorld Today that a new, 5,000-patient observational study will "cast a more focused light on the unmet need" in knocking down levels of LDL-C, as researchers will take "multiple snapshots" over a three-year period.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription